We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 11-20 of 1,166

Biosimilar Approvals in the US and Canada - the ‘Patent Dance’
  • Bereskin & Parr LLP
  • Canada, USA
  • December 30 2015

The US and Canada each provide an abbreviated pathway (or shortcut) for a biosimilar manufacturer to get a product approved. The shortcut allows for a

Canadian patent law: 2015 year in review
  • Gowling Lafleur Henderson LLP
  • Canada
  • January 13 2016

A successful patentee in a patent infringement action is entitled to monetary compensation in relation to the acts of infringement. In this regard

Patent utility update in Canada clarity may not be explicitly promised
  • SIM. IP Practice
  • Canada
  • June 4 2015

In the past five years, the Canadian Federal Court has invalidated several patents based on an arguably “technical” deficiency the

Proactive pharma patent enforcement on Canadian drug combos
  • Bereskin & Parr LLP
  • Canada
  • May 14 2015

The Canadian Patented Medicine (Notice of Compliance) Regulations ("NOC Regulations") allow a patent owner to apply to Federal Court to keep a

Federal court prohibits the approval of a generic prodrug CELLCEPT (mycophenolate mofetil)
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 26 2011

On July 13, 2011, the Federal Court allowed an application by Hoffman La-Roche Limited (“Roche”), pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. (“Apotex”) in respect of its generic version of the drug mycophenolate mofetil (“MMF”) until after the expiry of Canadian Patent No. 1,333,285 (the “285 Patent”

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Sandoz Canada v Abbott Laboratories, appeal and cross-appeal of PMNOC decision, Clarithromycin extended-release, June 22, 2010
  • Gowling Lafleur Henderson LLP
  • Canada
  • August 26 2010

Sandoz served a notice of allegation ("NOA") upon Abbott and filed an Abbreviated New Drug Submission ("ANDS") with respect to clarithromycin extended-release

Rx IP Update: 2015 Highlights
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 4 2016

In November 2014, Apotex discontinued its appeal to the Supreme Court of Canada (SCC) on the eve of the hearing of its appeal regarding the validity

Statements in a generic’s Product Monograph were not found to amount to an inducement to infringe
  • Borden Ladner Gervais LLP
  • Canada
  • April 13 2015

The Court has allowed a motion to strike portions of an application pursuant to Paragraph 6(5)(b) of the PM(NOC) Regulations. The generic respondent

“Pay for delay” gets a closer look in Canada
  • Sotos LLP
  • Canada
  • May 21 2015

The Canadian Competition Bureau is taking a “keen interest” in patent litigation settlements between brand and generic drug manufacturers